Last reviewed · How we verify
Cemiplimab plus REGN3767
Cemiplimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, enhancing T-cell activation and immune response against tumor cells.
Cemiplimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, enhancing T-cell activation and immune response against tumor cells. Used for Non-small cell lung cancer, PD-L1 ≥50%, Cutaneous squamous cell carcinoma.
At a glance
| Generic name | Cemiplimab plus REGN3767 |
|---|---|
| Sponsor | QuantumLeap Healthcare Collaborative |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
REGN3767, also known as cemiplimab, is a human monoclonal antibody that targets the programmed death receptor-1 (PD-1). By blocking PD-1, cemiplimab enhances the immune system's ability to detect and destroy cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 ≥50%
- Cutaneous squamous cell carcinoma
Common side effects
- Fatigue
- Rash
- Diarrhea
Key clinical trials
- Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (PHASE2)
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PHASE2)
- Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer (PHASE2)
- Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer (PHASE2)
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) (PHASE3)
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |